publication date: Oct. 25, 2019

Clinical Roundup

Phase III IMbrave150 study demonstrates improved OS + PFS in liver cancer

The phase III IMbrave150 study evaluating Tecentriq in combination with Avastin in people with unresectable hepatocellular carcinoma met its co-primary endpoints of overall survival and progression-free survival, compared with standard-of-care sorafenib.

The study, sponsored by Genentech, a unit of Roche, demonstrated statistically significant and clinically meaningful improvements in both primary endpoints.

This is the first phase III cancer immunotherapy study to show an improvement in OS and PFS in HCC, the most common form of liver cancer.

 

Novel imaging technology could reduce need for additional surgery after breast cancer resection

Wide Field Optical Coherence Tomography has the potential to significantly reduce the need for additional surgery after breast tumor resection, according to a study published in The Breast Journal.

In addition, the study’s researchers found that OCT images have the ability to delineate ductal carcinoma in situ at the margins. These tumor cells can be difficult to detect by any technique other than microscopy in the laboratory.

There’s already one device on the market, MarginProbe by Dune Medical, that FDA has cleared for use in identifying positive margins during breast cancer surgery in real time. The technology uses radio-frequency spectroscopy to probe the tissue and identify any cancer that may be remaining on the surface of the tissue removed from the breast.

“There’s no question that within the next five years, we’re going to have an imaging technology that’s going to be in later stage clinical trials, and it’s going to have a high degree of sensitivity to detect disease at the margin during surgeries … Continue reading Phase III IMbrave150 study demonstrates improved OS + PFS in liver cancer

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.